Allergan Unanimously Rejects Valeant’s Bid

May 12 (Bloomberg) -- Allergan board says the Valeant bid “substantially undervalues” the company and creates significant risks and uncertainties and is not in best interests of the company and shareholders. Tom Keene reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

Sales Check With Hudson's Bay CEO Jerry Storch
06:35 - Hudson's Bay CEO Jerry Storch weighs in on Black Friday sales. He speaks on "Bloomberg Markets." (Source: Bloomberg)
  • Black Friday Retail Sales: The Winners & the Losers
  • Battle of the Charts: Retail Traffic, Euro Versus Dollar
  • 2016 Will Be a Better Year for Stocks, Here's Why